These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 27010943)

  • 61. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
    Getaneh AM; Heijnsdijk EAM; Roobol MJ; de Koning HJ
    Cancer Med; 2020 Oct; 9(20):7742-7750. PubMed ID: 32813910
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    Dijkstra S; Govers TM; Hendriks RJ; Schalken JA; Van Criekinge W; Van Neste L; Grutters JPC; Sedelaar JPM; van Oort IM
    BJU Int; 2017 Nov; 120(5):659-665. PubMed ID: 28370948
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study.
    Hao S; Discacciati A; Eklund M; Heintz E; Östensson E; Elfström KM; Clements MS; Nordström T
    JAMA Oncol; 2022 Nov; 9(1):88-94. PubMed ID: 36355382
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Screening for proteinuria in US adults: a cost-effectiveness analysis.
    Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
    JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening.
    Garg V; Gu NY; Borrego ME; Raisch DW
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):327-42. PubMed ID: 23763530
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
    Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
    JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Individualized estimates of overdiagnosis in screen-detected prostate cancer.
    Gulati R; Inoue LY; Gore JL; Katcher J; Etzioni R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt367. PubMed ID: 24399850
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The socioeconomic implications of prostate-specific antigen screening.
    Benoit RM; Naslund MJ
    Urol Clin North Am; 1997 May; 24(2):451-8. PubMed ID: 9126243
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies.
    Etzioni R; Cha R; Cowen ME
    J Urol; 1999 Sep; 162(3 Pt 1):741-8. PubMed ID: 10458357
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prostate cancer, the PSA test and academic detailing in Australian general practice: an economic evaluation.
    Stone CA; May FW; Pinnock CB; Elwood M; Rowett DS
    Aust N Z J Public Health; 2005 Aug; 29(4):349-57. PubMed ID: 16222933
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
    Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
    Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.
    Uozumi J; Tokuda Y; Fujiyama C; Takagi N; Meiri H; Kuratomi K; Nakamura K; Ichigi Y; Yoshinaga H; Kinoshita N; Masaki Z
    Int J Urol; 2002 Jun; 9(6):334-9. PubMed ID: 12110098
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
    Govers TM; Caba L; Resnick MJ
    J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.